Vanguard Personalized Indexing Management LLC Boosts Stake in Merck & Co., Inc. $MRK

Vanguard Personalized Indexing Management LLC grew its position in shares of Merck & Co., Inc. (NYSE:MRK) by 20.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 385,886 shares of the company’s stock after acquiring an additional 66,115 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Merck & Co., Inc. were worth $40,618,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Venture Visionary Partners LLC raised its stake in shares of Merck & Co., Inc. by 5.4% in the 4th quarter. Venture Visionary Partners LLC now owns 43,913 shares of the company’s stock valued at $4,793,000 after acquiring an additional 2,250 shares during the period. Whalerock Point Partners LLC raised its holdings in Merck & Co., Inc. by 4.4% in the fourth quarter. Whalerock Point Partners LLC now owns 17,865 shares of the company’s stock valued at $1,880,000 after acquiring an additional 750 shares in the last quarter. Panagora Asset Management Inc. raised its stake in shares of Merck & Co., Inc. by 410.5% in the 4th quarter. Panagora Asset Management Inc. now owns 705,442 shares of the company’s stock valued at $74,255,000 after purchasing an additional 567,249 shares in the last quarter. Perryman Financial Advisory Inc. AD bought a new position in Merck & Co., Inc. during the 4th quarter worth approximately $5,902,000. Finally, Palisade Asset Management LLC lifted its stake in Merck & Co., Inc. by 3.4% during the fourth quarter. Palisade Asset Management LLC now owns 35,284 shares of the company’s stock worth $3,714,000 after purchasing an additional 1,161 shares during the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. JPMorgan Chase & Co. raised their price target on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a report on Monday, April 6th. Weiss Ratings lowered Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Zacks Research upgraded Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. Finally, Citigroup began coverage on Merck & Co., Inc. in a research report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and an average price target of $128.18.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck Animal Health announced a definitive agreement to acquire TARGAN, a poultry biodevice company, which could strengthen Merck’s animal health division and broaden its technology-driven growth opportunities. Merck Animal Health to Acquire TARGAN
• Positive Sentiment: Merck saw unusually heavy call option buying, with traders purchasing 170,441 calls, a sharp jump versus normal volume that often signals bullish expectations from sophisticated investors.
• Positive Sentiment: Wells Fargo reiterated a buy rating on Merck, while another article highlighted that Wall Street’s overall bullish view continues to keep MRK on investors’ radar.
• Neutral Sentiment: Merck has also been featured in broader market commentary and “most searched” lists, suggesting rising attention rather than a new fundamental catalyst.
• Neutral Sentiment: One article noted Merck’s recent trading uptick but said it lagged the broader market, indicating modest price strength rather than a major breakout. Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Merck & Co., Inc. Price Performance

NYSE MRK opened at $119.05 on Monday. The company has a 50-day moving average price of $116.55 and a two-hundred day moving average price of $113.32. Merck & Co., Inc. has a 52 week low of $76.66 and a 52 week high of $125.14. The stock has a market cap of $294.04 billion, a price-to-earnings ratio of 33.54, a price-to-earnings-growth ratio of 2.68 and a beta of 0.21. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The company had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Analysts forecast that Merck & Co., Inc. will post 5.17 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be paid a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 annualized dividend and a yield of 2.9%. Merck & Co., Inc.’s payout ratio is presently 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.